Year: 2012
Type: article
Study design: Observational Study
Abstract: AIMS/HYPOTHESIS: Autoantibodies to zinc transporter 8 (ZnT8A) are associated with risk of type 1 diabetes. Apart from the SLC30A8 gene itself, little is known about the genetic basis of ZnT8A. We hypothesise that other loci in addition to SLC30A8 are associated with ZnT8A. METHODS: The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years. Cases were tested at over 775,000 loci genome wide (including 53 type 1 diabetes associated regions) for association with positivity for ZnT8A. ZnT8A were also measured in an independent dataset of 855 family members with type 1 diabetes. RESULTS: Only FCRL3 on chromosome 1q23.1 and the HLA class I region were associated with positivity for ZnT8A. rs7522061T>C was the most associated single nucleotide polymorphism (SNP) in the FCRL3 region (p = 1.13 × 10(-16)). The association was confirmed in the family dataset (p ≤ 9.20 × 10(-4)). rs9258750A>G was the most associated variant in the HLA region (p = 2.06 × 10(-9) and p = 0.0014 in family cases). The presence of ZnT8A was not associated with HLA-DRB1, HLA-DQB1, HLA-A, HLA-B or HLA-C (p > 0.05). Unexpectedly, the two loci associated with the presence of ZnT8A did not alter risk of having type 1 diabetes, and the 53 type 1 diabetes risk loci did not influence positivity for ZnT8A, despite them being disease specific. CONCLUSIONS/INTERPRETATION: ZnT8A are not primary pathogenic factors in type 1 diabetes. Nevertheless, ZnT8A testing in combination with other autoantibodies facilitates disease prediction, despite the biomarker not being under the same genetic control as the disease.
Source: Diabetologia
Authors: J. M. M. Howson, S. Krause, H. Stevens, D. J. Smyth, J. M. Wenzlau, E. Bonifacio, J. Hutton, A. G. Ziegler, J. A. Todd, P. Achenbach
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
Funders: Juvenile Diabetes Research Foundation United States of America, Wellcome Trust, National Institute for Health and Care Research, British Heart Foundation, University of Cambridge, University of Leicester, European Commission, University of Bristol, Bundesministerium für Bildung und Forschung, U.S. Public Health Service, Medical Research Council, Cambridge Institute for Medical Research, University of Cambridge, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development
Awards: G1137313802, Novel immunotherapies for type 1 diabetes, G1833068706, UCHSC Diabetes and Endocrinology Research Center, Diabetes and Inflammation Laboratory., G2727724280, G2961485127, DIAbetes type 1 PRediction, Early Pathogenesis and Prevention, G3153491656, G3207356259, JDRF/WT Diabetes and Inflammation Laboratory., G393177772, NIHR Senior Investigator Award, G5568298347, A national DNA control series for genetic case-control studies based on the British 1958 birth cohort, G5702163051, Krankheitsbezogenes Kompetenznetz Diabetes mellitus (1.+2. Förderphase) - Thema Typ 1 Diabetes Immunologie - TP Z, 1, 16e, 9 (2. FP), TP DiMelli, Teen-Diab (1. FP), Type 1 Diabetes Genetics Consortium, G6531923824, G6692001510, Cambridge Institute for Medical Research (CIMR)., Systematic approaches to the evaluation of emerging coronary risk markers. Large-scale epidemiological analyses of existing data and stored biological samples (renewal), G8900108227, The genetics of weight, BMI, adiposity and obesity, Design and implementation of large-scale genetic association studies of commondiseases., G911899757
OpenAlex ID: W2055612236
